Emerging drugs for bipolar disorder

Expert Opinion on Emerging Drugs

Volumn 15, Issue 3, 2010, Pages 453-466

  Sanches, Marsal ^a   Newberg, Andrew R ^b   Soares, Jair C ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Bipolar disorder; Mood disorders; Mood stabilizers; Pharmacology; Therapeutics

Indexed keywords

AGOMELATINE; ALLOPURINOL; AMANTADINE; ANTIINFLAMMATORY AGENT; ARIPIPRAZOLE; CARBAMAZEPINE; CELECOXIB; CLOZAPINE; CYCLOSERINE; DIPYRIDAMOLE; DONEPEZIL; FLUOXETINE PLUS OLANZAPINE; KETOCONAZOLE; LAMOTRIGINE; LITHIUM; MEMANTINE; MODAFINIL; MOOD STABILIZER; NEUROPROTECTIVE AGENT; OLANZAPINE; PRAMIPEXOLE; PROTEIN KINASE C INHIBITOR; QUETIAPINE; RILUZOLE; RISPERIDONE; SCOPOLAMINE; TAMOXIFEN; UNINDEXED DRUG; VALPROIC ACID; ZIPRASIDONE;

BIPOLAR DEPRESSION; BIPOLAR DISORDER; COGNITIVE DEFECT; DRUG MECHANISM; HUMAN; NONHUMAN; REVIEW;

ANIMALS; ANTIMANIC AGENTS; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; COGNITION DISORDERS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS;

EID: 77955895082     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.2010.492393     Document Type: Review

References (97)

1. Soares JC. Can brain-imaging studies provide a 'mood stabilizer signature?'. Mol Psychiatry 2002;7(Suppl 1):S64-70
2. American Psychiatric Association. Task Force on DSM-IV. Diagnostic and statistical manual of mental disorders: DSM-IV-TR. 4th edition. American Psychiatric Association, Washington, DC; 2000
3. Kessler RC, Chiu WT, Demler O, et al. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National comorbidity survey replication. Arch Gen Psychiatry 2005;62:617-627 (Pubitemid 40973437)
4. Merikangas KR, Akiskal HS, Angst J, et al. Lifetime and 12-month prevalence of bipolar spectrum disorder in the National comorbidity survey replication. Arch Gen Psychiatry 2007;64:543-552
5. Hirschfeld RM, Calabrese JR, Weissman MM, et al. Screening for bipolar disorder in the community. J Clin Psychiatry 2003;64:53-59
6. Fagiolini A, Kupfer DJ, Masalehdan A, et al. Functional impairment in the remission phase of bipolar disorder. Bipolar Disord 2005;7:281-285
7. Kupfer DJ. The increasing medical burden in bipolar disorder. JAMA 2005;293:2528-2530
8. Kilbane EJ, Gokbayrak NS, Galynker I, et al. A review of panic and suicide in bipolar disorder: does comorbidity increase risk? J Affect Disord 2009;115:1-10
9. Martinez-Aran A, Vieta E, Reinares M, et al. Cognitive function across manic or hypomanic, depressed, and euthymic states in bipolar disorder. Am J psychiatry 2004;161:262-270
10. Gruber S, Rathgeber K, Braunig P, Gauggel S. Stability and course of neuropsychological deficits in manic and depressed bipolar patients compared to patients with major depression. J Affect Disord 2007;104:61-71
11. Malhi GS, Ivanovski B, Hadzi-Pavlovic D, et al. Neuropsychological deficits and functional impairment in bipolar depression, hypomania and euthymia. Bipolar Disord 2007;9:114-125
12. Martinez-Aran A, Vieta E, Colom F, et al. Cognitive impairment in euthymic bipolar patients: implications for clinical and functional outcome. Bipolar Disord 2004;6:224-232
13. Ferrier IN, Stanton BR, Kelly TP, Scott J. Neuropsychological function in euthymic patients with bipolar disorder. Br J Psychiatry 1999;175:246-251 (Pubitemid 29406594)
14. Zubieta JK, Huguelet P, O'Neil RL, Giordani BJ. Cognitive function in euthymic bipolar I disorder. Psychiatry Res 2001;102:9-20
15. Rossi A, Arduini L, Daneluzzo E, et al. Cognitive function in euthymic bipolar patients, stabilized schizophrenic patients, and healthy controls. J Psychiatr Res 2000;34:333-339
16. Rubinsztein JS, Michael A, Paykel ES, Sahakian BJ. Cognitive impairment in remission in bipolar affective disorder. Psychol Med 2000;30:1025-1036
17. Thompson JM, Gallagher P, Hughes JH, et al. Neurocognitive impairment in euthymic patients with bipolar affective disorder. Br J Psychiatry 2005;186:32-40
18. van Gorp WG, Altshuler L, Theberge DC, et al. Cognitive impairment in euthymic bipolar patients with and without prior alcohol dependence. A preliminary study. Arch Gene Psychiatry 1998;55:41-46
19. Torres IJ, Boudreau VG, Yatham LN. Neuropsychological functioning in euthymic bipolar disorder: a meta-analysis. Acta Psychiatr Scand Suppl 2007;434:17-26
20. Robinson LJ, Thompson JM, Gallagher P, et al. A meta-analysis of cognitive deficits in euthymic patients with bipolar disorder. J Affect Disord 2006;93:105-115
21. Martinez-Aran A, Vieta E, Colom F, et al. Do cognitive complaints in euthymic bipolar patients reflect objective cognitive impairment? Psychother Psychosom 2005;74:295-302
22. Huxley N, Baldessarini RJ. Disability and its treatment in bipolar disorder patients. Bipolar Disord 2007;9:183-196
23. Altshuler L, Tekell J, Biswas K, et al. Executive function and employment status among veterans with bipolar disorder. Psychiatr Serv 2007;58:1441-1447
24. Perlis RH, Ostacher MJ, Patel JK, et al. Predictors of recurrence in bipolar disorder: primary outcomes from the systematic treatment enhancement program for bipolar disorder (STEP-BD). Am J Psychiatry 2006;163:217-224
25. Goldberg JF, Chengappa KN. Identifying and treating cognitive impairment in bipolar disorder. Bipolar Disord 2009;11(Suppl 2):123-137
26. Brambilla P, Barale F, Soares JC. Atypical antipsychotics and mood stabilization in bipolar disorder. Psychopharmacology (Berl) 2003;166:315-332
27. Suppes T, Dennehy EB, Hirschfeld RM, et al. The Texas implementation of medication algorithms: update to the algorithms for treatment of bipolar I disorder. J Clin Psychiatry 2005;66:870-886
28. Haddad PM, Sharma SG. Adverse effects of atypical antipsychotics: differential risk and clinical implications. CNS drugs 2007;21:911-936
29. Muzina DJ, Colangelo E, Manning JS, Calabrese JR. Differentiating bipolar disorder from depression in primary care. Clevel Clin J Med 2007, 74: 89, 92,5-9 passim
30. Dennehy EB, Bauer MS, Perlis RH, et al. Concordance with treatment guidelines for bipolar disorder: data from the systematic treatment enhancement program for bipolar disorder. Psychopharmacol Bull 2007;40:72-84
31. Bauer MS, Biswas K, Kilbourne AM. Enhancing multiyear guideline concordance for bipolar disorder through collaborative care. Am J Psychiatry 2009;166:1244-1250
32. Newberg AR, Catapano LA, Zarate CA, Manji HK. Neurobiology of bipolar disorder. Expert Rev Neurother 2008;8:93-110
33. Faden AI, Stoica B. Neuroprotection: challenges and opportunities. Arch Neurol 2007;64:794-800
34. Peled A. Plasticity imbalance in mental disorders the neuroscience of psychiatry: implications for diagnosis and research. Med Hypotheses 2005;65:947-952
35. Machado-Vieira R, Manji HK, Zarate CA Jr. The role of lithium in the treatment of bipolar disorder: convergent evidence for neurotrophic effects as a unifying hypothesis. Bipolar Disord 2009;11(Suppl 2):92-109
36. Sassi RB, Nicoletti M, Brambilla P, et al. Increased gray matter volume in lithium-treated bipolar disorder patients. Neurosci Lett 2002;329:243-245
37. Moore GJ, Bebchuk JM, Hasanat K, et al. Lithium increases N-acetyl-aspartate in the human brain: in vivo evidence in support of bcl-2's neurotrophic effects? Biol Psychiatry 2000;48:1-8
38. Gould TD, Manji HK. Glycogen synthase kinase-3: a putative molecular target for lithium mimetic drugs. Neuropsychopharmacology 2005;30:1223-1237
39. O'Brien WT, Klein PS. Validating GSK3 as an in vivo target of lithium action. Biochem Soc Trans 2009;37:1133-1138
40. Yasuda S, Liang MH, Marinova Z, et al. The mood stabilizers lithium and valproate selectively activate the promoter IV of brain-derived neurotrophic factor in neurons. Mol Psychiatry 2009;14:51-59
41. Young W. Review of lithium effects on brain and blood. Cell Transplant 2009;18:951-975
42. Chen G, Zeng WZ, Yuan PX, et al. The mood-stabilizing agents lithium and valproate robustly increase the levels of the neuroprotective protein bcl-2 in the CNS. J Neurochem 1999;72:879-882
43. Bai O, Zhang H, Li XM. Antipsychotic drugs clozapine and olanzapine upregulate bcl-2 mRNA and protein in rat frontal cortex and hippocampus. Brain Res 2004;1010:81-86
44. Bai O, Chlan-Fourney J, Bowen R, et al. Expression of brain-derived neurotrophic factor mRNA in rat hippocampus after treatment with antipsychotic drugs. J Neurosci Res 2003;71:127-131
45. Salvadore G, Drevets WC, Henter ID, et al. Early intervention in bipolar disorder, part II: therapeutics. Early Interv Psychiatry 2008;2:136-146
46. Zarate CA Jr, Manji HK. Bipolar disorder: candidate drug targets. Mt Sinai J Med 2008;75:226-247
47. Goldberg JF, Burdick KE, Endick CJ. Preliminary randomized, double-blind, placebo-controlled trial of pramipexole added to mood stabilizers for treatment-resistant bipolar depression. Am J Psychiatry 2004;161:564-566
48. Zarate CA Jr, Payne JL, Singh J, et al. Pramipexole for bipolar II depression: a placebo-controlled proof of concept study. Biol Psychiatry 2004;56:54-60
49. Alda M, Hajek T, Calkin C, O'Donovan C. Treatment of bipolar disorder: new perspectives. Ann Med 2009;41:186-196
50. Chaturvedi RK, Beal MF. Mitochondrial approaches for neuroprotection. Ann NY Acad Sci 2008;1147:395-412
51. Kato T. The role of mitochondrial dysfunction in bipolar disorder. Drug News Perspect 2006;19:597-602
52. Ng WX, Lau IY, Graham S, Sim K. Neurobiological evidence for thalamic, hippocampal and related glutamatergic abnormalities in bipolar disorder: a review and synthesis. Neurosci Biobehav Rev 2009;33:336-354
53. Dean OM, van den Buuse M, Bush AI, et al. A role for glutathione in the pathophysiology of bipolar disorder and schizophrenia? Animal models and relevance to clinical practice. Curr Med Chem 2009;16:2965-2976
54. Sourial-Bassillious N, Rydelius PA, Aperia A, Aizman O. Glutamate-mediated calcium signaling: a potential target for lithium action. Neuroscience 2009;161:1126-1134
55. Prica C, Hascoet M, Bourin M. Antidepressant-like effect of lamotrigine is reversed by veratrine: a possible role of sodium channels in bipolar depression. Behav Brain Res 2008;191:49-54
56. Bowden CL. Anticonvulsants in bipolar disorders: current research and practice and future directions. Bipolar Disord 2009;11(Suppl 2):20-33
57. Franberg O, Wiker C, Marcus MM, et al. Asenapine, a novel psychopharmacologic agent: preclinical evidence for clinical effects in schizophrenia. Psychopharmacology (Berl) 2008;196:417-429
58. Zarate CA Jr, Singh JB, Quiroz JA, et al. A double-blind, placebo-controlled study of memantine in the treatment of major depression. Am J Psychiatry 2006;163:153-155
59. Ferguson JM, Shingleton RN. An open-label, flexible-dose study of memantine in major depressive disorder. Clin Neuropharmacol 2007;30:136-144
60. Brown ES, Vazquez M, Nakamura A. Randomized, placebo-controlled, crossover trial of memantine for cognitive changes with corticosteroid therapy. Biol Psychiatry 2008;64:727-729
61. Moryl E, Danysz W, Quack G. Potential antidepressive properties of amantadine, memantine and bifemelane. Pharmacol Toxicol 1993;72:394-397
62. Bode L, Dietrich DE, Stoyloff R, et al. Amantadine and human Borna disease virus in vitro and in vivo in an infected patient with bipolar depression. Lancet 1997;349:178-179
63. Ohlmeier MD, Sieg S, Emrich HM, Dietrich DE. Amantadine in acute bipolar mania. Aust NZ J Psychiatry 2007;41:194
64. Aan het Rot M, Collins KA, Murrough JW, et al. Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biol Psychiatry 2010;67:139-145
65. Zarate CA Jr, Quiroz JA, Singh JB, et al. An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression. Biol Psychiatry 2005;57:430-432
66. Brennan BP, Hudson JI, Jensen JE, et al. Rapid enhancement of glutamatergic neurotransmission in bipolar depression following treatment with riluzole. Neuropsychopharmacology 2010;35(3):834-846
67. Conn PJ, Lindsley CW, Jones CK. Activation of metabotropic glutamate receptors as a novel approach for the treatment of schizophrenia. Trends Pharmacol Sci 2009;30:25-31
68. Zarate CA Jr, Singh JB, Carlson PJ, et al. Efficacy of a protein kinase C inhibitor (tamoxifen) in the treatment of acute mania: a pilot study. Bipolar Disord 2007;9:561-570
69. Yildiz A, Guleryuz S, Ankerst DP, et al. Protein kinase C inhibition in the treatment of mania: a double-blind, placebo-controlled trial of tamoxifen. Arch Gen Psychiatry 2008;65:255-263
70. Noaghiul S, Hibbeln JR. Cross-national comparisons of seafood consumption and rates of bipolar disorders. Am J Psychiatry 2003;160:2222-2227
71. McNamara RK, Ostrander M, Abplanalp W, et al. Modulation of phosphoinositide-protein kinase C signal transduction by omega-3 fatty acids: implications for the pathophysiology and treatment of recurrent neuropsychiatric illness. Prostaglandins Leukot Essent Fatty Acids 2006;75:237-257
72. Montgomery P, Richardson AJ. Omega-3 fatty acids for bipolar disorder. Cochrane Database Syst Rev 2008:CD005169
73. Kraguljac NV, Montori VM, Pavuluri M, et al. Efficacy of omega-3 fatty acids in mood disorders - a systematic review and metaanalysis. Psychopharmacol Bull 2009;42:39-54
74. Daban C, Vieta E, Mackin P, Young AH. Hypothalamic-pituitary-adre- nal axis and bipolar disorder. Psychiatr Clin North Am 2005;28:469-480
75. Hoschl C, Hajek T. Hippocampal damage mediated by corticosteroids - a neuropsychiatric research challenge. Eur Arch Psychiatry Clin Neurosci 2001;251(Suppl 2):II81-8
76. Sala M, Perez J, Soloff P, et al. Stress and hippocampal abnormalities in psychiatric disorders. Eur Neuropsychopharmacol 2004;14:393-405
77. Young AH, Gallagher P, Watson S, et al. Improvements in neurocognitive function and mood following adjunctive treatment with mifepristone (RU-486) in bipolar disorder. Neuropsychopharmacology 2004;29:1538-1545
78. Brown ES, Bobadilla L, Rush AJ. Ketoconazole in bipolar patients with depressive symptoms: a case series and literature review. Bipolar Disord 2001;3:23-29
79. Zobel AW, Nickel T, Kunzel HE, et al. Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated. J Psychiatr Res 2000;34:171-181
80. Binneman B, Feltner D, Kolluri S, et al. A 6-week randomized, placebo-controlled trial of CP-316,311 (a selective CRH1 antagonist) in the treatment of major depression. Am J Psychiatry 2008;165:617-620
81. Hallam KT, Olver JS, Chambers V, et al. The heritability of melatonin secretion and sensitivity to bright nocturnal light in twins. Psychoneuroendocrinology 2006;31:867-875
82. Calabrese JR, Guelfi JD, Perdrizet-Chevallier C. Agomelatine adjunctive therapy for acute bipolar depression: preliminary open data. Bipolar Disord 2007;9(6):628-635
83. Hafizi S, Chandra P, Cowen J. Neurokinin-1 receptor antagonists as novel antidepressants: trials and tribulations. Br J Psychiatry 2007;191:282-284
84. Keller M, Montgomery S, Ball W, et al. Lack of efficacy of the substance p (neurokinin1 receptor) antagonist aprepitant in the treatment of major depressive disorder. Biol Psychiatry 2006;59:216-223
85. Goldstein BI, Kemp DE, Soczynska JK, McIntyre RS. Inflammation and the phenomenology, pathophysiology, comorbidity, and treatment of bipolar disorder: a systematic review of the literature. J Clin Psychiatry 2009;70:1078-1090
86. Kim YK, Jung HG, Myint AM, et al. Imbalance between pro-inflammatory and anti-inflammatory cytokines in bipolar disorder. J Affect Disord 2007;104:91-95
87. Rao JS, Rapoport SI. Mood-stabilizers target the brain arachidonic acid cascade. Curr Mol Pharmacol 2009;2:207-214
88. Nery FG, Monkul ES, Hatch JP, et al. Celecoxib as an adjunct in the treatment of depressive or mixed episodes of bipolar disorder: a double-blind, randomized, placebo-controlled study. Hum Psychopharmacol 2008;23:87-94
89. Furey ML, Drevets WC. Antidepressant efficacy of the antimuscarinic drug scopolamine: a randomized, placebo-controlled clinical trial. Arch Gen Psychiatry 2006;63:1121-1129
90. Burt T, Sachs GS, Demopulos C. Donepezil in treatment-resistant bipolar disorder. Biol Psychiatry 1999;45:959-964
91. Eden Evins A, Demopulos C, Nierenberg A, et al. A double-blind, placebo-controlled trial of adjunctive donepezil in treatment-resistant mania. Bipolar Disord 2006;8:75-80
92. Gildengers AG, Butters MA, Chisholm D, et al. A 12-week open-label pilot study of donepezil for cognitive functioning and instrumental activities of daily living in late-life bipolar disorder. Int J Geriatr Psychiatry 2008;23:693-698
93. Machado-Vieira R, Soares JC, Lara DR, et al. A double-blind, randomized, placebo-controlled 4-week study on the efficacy and safety of the purinergic agents allopurinol and dipyridamole adjunctive to lithium in acute bipolar mania. J Clin Psychiatry 2008;69:1237-1245
94. Akhondzadeh S, Milajerdi MR, Amini H, Tehrani-Doost M. Allopurinol as an adjunct to lithium and haloperidol for treatment of patients with acute mania: a double-blind, randomized, placebo-controlled trial. Bipolar Disord 2006;8:485-489
95. Frye MA, Grunze H, Suppes T, et al. A placebo-controlled evaluation of adjunctive modafinil in the treatment of bipolar depression. Am J Psychiatry 2007,164: 1242-1249
96. Rush AJ, Post RM, Nolen WA, et al. Methodological issues in developing new acute treatments for patients with bipolar illness. Biol Psychiatry 2000;48:615-624
97. Mathew SJ, Manji HK, Charney DS. Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology 2008;33:2080-2092